Literature DB >> 25267926

The Diversion of Prescription Opioid Analgesics.

James A Inciardi1, Hilary L Surratt1, Yamilka Lugo1, Theodore J Cicero2.   

Abstract

Prescription drug diversion involves the unlawful channeling of regulated pharmaceuticals from legal sources to the illicit marketplace, and can occur along all points in the drug delivery process -- from the original manufacturing site, to the wholesale distributor, the physician's office, the retail pharmacy, or the patient. Although a number of recent scientific papers have discussed the problems associated with diversion, empirical data on the scope and magnitude of diversion are limited in the literature. This paper presents findings from a national diversion survey being conducted as part of risk management initiatives supported by Denver Health and Hospital Authority, designed to monitor the abuse and diversion of a variety of prescription opioid analgesics. On a quarterly basis, diversion investigators in 300 jurisdictions distributed throughout the 50 states, the District of Columbia, and Puerto Rico are sent short questionnaires designed to elicit data on the extent of drug diversion in their areas. During the 20-quarter survey period reported in this paper, a total of 64,655 cases of prescription drug diversion were reported from all of the participating sites. The most widely diverted opioid was hydrocodone, in that it was mentioned in 38.2% of the cases, followed by oxycodone, mentioned in 24.3% of the cases. By contrast, the proportions of cases in which other opioids were mentioned were significantly smaller. The diversion of opioids appears in all 50 states, the District of Columbia, and Puerto Rico, with especially high concentrations in rural areas. How all of these prescription opioids are being diverted to the street, however, is not altogether clear, and in many ways, diversion is a "black box" requiring concentrated systematic study.

Entities:  

Year:  2007        PMID: 25267926      PMCID: PMC4176900     

Source DB:  PubMed          Journal:  Law Enforc Exec Forum        ISSN: 1552-9908


  21 in total

1.  Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential.

Authors:  L Simoni-Wastila; C Tompkins
Journal:  Subst Use Misuse       Date:  2001 Jul-Aug       Impact factor: 2.164

2.  Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey.

Authors:  Sean Esteban McCabe; John R Knight; Christian J Teter; Henry Wechsler
Journal:  Addiction       Date:  2005-01       Impact factor: 6.526

3.  Methaqualone abuse patterns, diversion paths and adverse reactions.

Authors:  J A Inciardi; D M Petersen; C D Chambers
Journal:  JFMA       Date:  1974-04

Review 4.  An overview of prescription drug misuse and abuse: defining the problem and seeking solutions.

Authors:  B B Wilford; J Finch; D J Czechowicz; D Warren
Journal:  J Law Med Ethics       Date:  1994       Impact factor: 1.718

5.  Mechanisms of prescription drug diversion among drug-involved club- and street-based populations.

Authors:  James A Inciardi; Hilary L Surratt; Steven P Kurtz; Theodore J Cicero
Journal:  Pain Med       Date:  2007-03       Impact factor: 3.750

6.  The use, misuse and diversion of prescription stimulants among middle and high school students.

Authors:  Sean Esteban McCabe; Christian J Teter; Carol J Boyd
Journal:  Subst Use Misuse       Date:  2004-06       Impact factor: 2.164

7.  A profile of OxyContin addiction.

Authors:  Lon R Hays
Journal:  J Addict Dis       Date:  2004

8.  Problems of methadone diversion and implications for control.

Authors:  R B Resnick
Journal:  Int J Addict       Date:  1977-10

9.  Use of prescription forgeries in a drug abuse surveillance network.

Authors:  U Bergman; M L Dahl-Puustinen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more
  24 in total

1.  Patterns of prescription medication diversion among drug dealers.

Authors:  Khary K Rigg; Steven P Kurtz; Hilary L Surratt
Journal:  Drugs (Abingdon Engl)       Date:  2012

2.  Prescription Drug Abuse & Diversion: Role of the Pain Clinic.

Authors:  Khary K Rigg; Samantha J March; James A Inciardi
Journal:  J Drug Issues       Date:  2010

3.  Friends and relatives as sources of prescription opioids for misuse among young adults: The significance of physician source and race/ethnic differences.

Authors:  Jason A Ford; Corey Pomykacz; Alec Szalewski; Sean Esteban McCabe; Ty S Schepis
Journal:  Subst Abus       Date:  2019-07-11       Impact factor: 3.716

4.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

5.  The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation.

Authors:  Margrét V Bjarnadóttir; David R Anderson; Kislaya Prasad; Ritu Agarwal; D Alan Nelson
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

6.  A descriptive analysis of drugged driving among rural DUI offenders.

Authors:  J Matthew Webster; Megan F Dickson; Michele Staton
Journal:  Traffic Inj Prev       Date:  2018-07-04       Impact factor: 1.491

Review 7.  Inappropriate opioid prescription after surgery.

Authors:  Mark D Neuman; Brian T Bateman; Hannah Wunsch
Journal:  Lancet       Date:  2019-04-13       Impact factor: 79.321

8.  The "black box" of prescription drug diversion.

Authors:  James A Inciardi; Hilary L Surratt; Theodore J Cicero; Steven P Kurtz; Steven S Martin; Mark W Parrino
Journal:  J Addict Dis       Date:  2009-10

9.  Diversion of benzodiazepines through healthcare sources.

Authors:  Gladys E Ibañez; Maria A Levi-Minzi; Khary K Rigg; Angela D Mooss
Journal:  J Psychoactive Drugs       Date:  2013 Jan-Mar

10.  Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment.

Authors:  James A Inciardi; Hilary L Surratt; Theodore J Cicero; Ronald A Beard
Journal:  Pain Med       Date:  2009-04       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.